bpc-157 uses side effects clinical studies BPC-157: Tendon Repair and More Regeneration or Risk? A Narrative
Description
CLDN-2, CLDN-4 and JAM-1 expression was increased in 0.8 mM GDC treated monolayers ( P 0.05)
High-strength appeal: At 50mg per capsule, this version by SWISS Pharmaceuticals caters to users who favour potent, high-concentration designer compounds
doi: 10.1016/s1078-5884(98)80184-6
Research confirms this consistently
